See more : Toubujyuhan Co.,Ltd. (3297.T) Income Statement Analysis – Financial Results
Complete financial analysis of Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hefei Lifeon Pharmaceutical Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- Corner Growth Acquisition Corp. (COOL) Income Statement Analysis – Financial Results
- Commerce Planet, Inc. (CPLT) Income Statement Analysis – Financial Results
- Orexplore Technologies Limited (OXT.AX) Income Statement Analysis – Financial Results
- Captain Pipes Limited (CAPPIPES.BO) Income Statement Analysis – Financial Results
- US Nuclear Corp. (UCLE) Income Statement Analysis – Financial Results
Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ)
About Hefei Lifeon Pharmaceutical Co., Ltd.
Hefei Lifeon Pharmaceutical Co., Ltd. engages research, development, production, and sales of pharmaceutical preparations and an active ingredient (APIs). It offers APIs, such as succimer, urea, paeonol, felodipine, doxazosin mesylate, zofenopril calcium, troxerutin, and sodium 2,3-dimercapto-1-propanesulfonate; medicinal preparations comprising felodipine sustained release tablets, doxazosin mesylate extended-release tablets, melbinum glipizide tablet, yiqihewei capsule, kunning granule, armillariella oral solution, paeonol ointment, urea and vitamin e cream, Kecuo Yintong gel, and Compound Golden Larch bark gel; and plant extracts, including clove oil, evening primrose oil, herba clinopodii P.E, quercetin, and dihydroquercetin. The company also operates retail chain of pharmaceuticals. Hefei Lifeon Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Hefei, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.90B | 2.58B | 2.27B | 1.89B | 1.65B | 1.42B | 1.17B | 1.03B | 962.17M | 877.72M | 733.32M |
| Cost of Revenue | 922.20M | 1.62B | 1.37B | 1.26B | 1.13B | 998.93M | 908.95M | 839.69M | 786.35M | 709.42M | 598.25M |
| Gross Profit | 978.59M | 964.28M | 907.17M | 633.64M | 517.23M | 425.65M | 257.62M | 188.48M | 175.82M | 168.30M | 135.07M |
| Gross Profit Ratio | 51.48% | 37.38% | 39.91% | 33.45% | 31.35% | 29.88% | 22.08% | 18.33% | 18.27% | 19.18% | 18.42% |
| Research & Development | 79.91M | 73.80M | 65.86M | 43.31M | 37.44M | 23.79M | 18.39M | 11.80M | 9.19M | 9.10M | 6.71M |
| General & Administrative | 21.91M | 15.60M | 11.02M | 14.12M | 8.64M | 16.12M | 6.15M | 22.44M | 23.50M | 21.24M | 17.53M |
| Selling & Marketing | 534.56M | 616.39M | 605.24M | 393.81M | 328.06M | 258.87M | 119.00M | 71.39M | 85.67M | 87.13M | 67.26M |
| SG&A | 651.01M | 631.98M | 616.27M | 407.92M | 336.70M | 274.99M | 125.15M | 93.83M | 109.16M | 108.37M | 84.80M |
| Other Expenses | -7.60M | 47.67M | 42.46M | 26.79M | 23.99M | 153.36K | 1.52M | 6.03M | 5.77M | 4.30M | 2.51M |
| Operating Expenses | 723.32M | 753.46M | 724.59M | 478.03M | 398.14M | 318.34M | 164.15M | 110.47M | 112.76M | 111.85M | 87.77M |
| Cost & Expenses | 1.65B | 2.37B | 2.09B | 1.74B | 1.53B | 1.32B | 1.07B | 950.16M | 899.11M | 821.27M | 686.02M |
| Interest Income | 4.65M | 4.39M | 3.35M | 4.30M | 2.43M | 1.18M | 735.48K | 219.56K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.40M | 890.23K | 1.36M | 244.64K | 1.14M | 2.60M | 3.13M | 2.54M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 47.34M | 38.21M | 38.49M | 16.16M | 15.17M | 14.13M | 13.60M | 13.04M | 11.07M | 11.29M | 10.45M |
| EBITDA | 305.10M | 283.29M | 238.19M | 173.62M | 138.26M | 125.42M | 108.40M | 91.04M | 74.12M | 67.74M | 57.75M |
| EBITDA Ratio | 16.05% | 10.99% | 10.38% | 9.22% | 8.43% | 8.92% | 9.33% | 9.46% | 7.80% | 7.95% | 8.90% |
| Operating Income | 255.27M | 240.05M | 192.45M | 157.44M | 118.84M | 108.27M | 89.96M | 75.14M | 58.34M | 50.26M | 37.93M |
| Operating Income Ratio | 13.43% | 9.31% | 8.47% | 8.31% | 7.20% | 7.60% | 7.71% | 7.31% | 6.06% | 5.73% | 5.17% |
| Total Other Income/Expenses | 2.15M | -231.60K | 5.68M | -497.60K | 2.78M | 153.36K | 1.52M | 6.03M | 5.50M | 4.27M | 2.01M |
| Income Before Tax | 257.42M | 239.82M | 194.84M | 156.94M | 121.62M | 108.43M | 91.47M | 81.17M | 63.84M | 54.53M | 39.94M |
| Income Before Tax Ratio | 13.54% | 9.30% | 8.57% | 8.28% | 7.37% | 7.61% | 7.84% | 7.89% | 6.63% | 6.21% | 5.45% |
| Income Tax Expense | 23.53M | 30.22M | 22.61M | 21.82M | 16.48M | 16.76M | 14.65M | 13.71M | 11.98M | 9.71M | 7.10M |
| Net Income | 226.67M | 209.25M | 172.23M | 135.12M | 105.14M | 91.66M | 76.82M | 67.46M | 53.82M | 47.02M | 36.69M |
| Net Income Ratio | 11.93% | 8.11% | 7.58% | 7.13% | 6.37% | 6.43% | 6.59% | 6.56% | 5.59% | 5.36% | 5.00% |
| EPS | 1.18 | 1.34 | 1.10 | 0.86 | 0.67 | 0.81 | 0.69 | 0.60 | 0.49 | 0.42 | 0.33 |
| EPS Diluted | 1.18 | 1.34 | 1.10 | 0.86 | 0.67 | 0.81 | 0.69 | 0.60 | 0.49 | 0.42 | 0.33 |
| Weighted Avg Shares Out | 191.56M | 156.56M | 156.56M | 156.56M | 156.56M | 113.07M | 111.92M | 111.77M | 110.93M | 111.93M | 110.72M |
| Weighted Avg Shares Out (Dil) | 191.56M | 156.56M | 156.56M | 156.56M | 156.56M | 113.07M | 111.92M | 111.78M | 110.93M | 111.93M | 110.73M |
Source: https://incomestatements.info
Category: Stock Reports